Innovative spin-offs

Max Planck Innovation has accompanied SuppreMol right from the start. As early as the pre-seed phase, the startup and portfolio managers advised SuppreMol intensively, supporting it successfully in the search for an initial investment community. They later accompanied us as part of the supervisory board until takeover by Baxter.

Professor Dr. Uwe Jacob
Co-founder and former CSO of
SuppreMol GmbH

I experienced Max Planck Innovation as a valuable and trustworthy partner in two spin-offs. All our many contacts there supported KonTEM GmbH as well as ProteoPlex GmbH from the pre-seed phase over the entire life cycle to a successful exit (in the case of KonTEM) with tremendous commitment and major expertise, thereby contributing significantly to entrepreneurial success.

Jorg Wamser
Managing Director
ProteoPlex GmbH

Max Planck Innovation accompanied Abberior Instruments in an advisory role in the pre-seed phase, having contributed its sound expertise regarding all aspects of start-up business. Thanks to numerous license agreements with Max Planck Innovation, Abberior Instrument is able to implement innovative inventions from the Max Planck Institutes rapidly in its products.

Dr. Lars Kastrup
Research & Development | Manager Intellectual Property Rights
Abberior Instruments GmbH

Max Planck Innovation has accompanied Targenomix right from the start. Especially in the pre-seed phase, the legal and start-up experience of Max Planck Innovation was extremely important for a successful conclusion of the complex and extensive cooperation agreement between Bayer Crop Science and Targenomix.

Prof. Dr. Lothar Willmitzer
Co-founder
Targenomix

The collaboration with MI really helped us to incorporate our scientific knowledge in a business concept. It is very important to have such experienced advisors on board to assist founders with help and advice and always act in their interests.

Dr. Moritz Horn
CEO
Acus Laboratories GmbH

My experience with Max Planck Innovation has revealed it to be a highly competent and knowledgeable partner in the patenting of substance classes for oligomer modulation in conjunction with neurodegeneration, the spin-off of the company MODAG between 2009 and 2013 and the series A financing of the same company in 2019. As such, it acted highly constructively and with success in mind – not only in respect to content and legal questions but also in the negotiations with a sense of proportion and diplomacy. Special thanks for the cooperation now in its 10th year to the responsible management team, who pondered over contract texts sometimes well into the midnight hours under time pressure for series A, thereby ensuring the success of the round and now enabling the testing of neurodegeneration drugs in humans.

Prof. Dr. Christian Griesinger
MPI for biophysical chemistry
Co-founder MODAG GmbH